On September 20, 2019, the FDA officially approved the marketing application of semaglutide for improving blood sugar control in patients with type 2 diabetes in combination with diet and exercise. Semaglutide is a human GLP-1 analogue with high albumin affinity and a long half-life, enabling once-weekly administration to stimulate insulin secretion and inhibit glucagon secretion in a blood sugar-dependent manner.
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Semaglutide is a <strong>GLP-1 receptor agonist</strong> synthesized via solid-phase peptide synthesis. Its molecular formula is C<sub>31</sub>H<sub>48</sub>N<sub>8</sub>O<sub>6</sub> with CAS No. 910463-68-2.</p>
<h3>Application</h3>
<ul>
<li><strong>Pharmaceutical Manufacturing:</strong> Production of injectable solutions for Type 2 diabetes management.</li>
<li><strong>Obesity Treatment:</strong> Development of weight-loss therapeutics under regulatory approval.</li>
<li><strong>R&D Supply:</strong> Provision of high-purity API for clinical trials and formulation studies.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly contraindicated in patients with personal or family history of medullary thyroid carcinoma. Store powder at -20°C protected from light; maintain cold chain logistics during transport to ensure stability.</p>